Accuray (NASDAQ:ARAY) Announces Earnings Results

Accuray (NASDAQ:ARAY) issued its earnings results on Wednesday. The medical equipment provider reported $0.02 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.01) by $0.03, Zacks reports. Accuray had a negative return on equity of 36.93% and a negative net margin of 3.72%. Accuray updated its FY 2025 guidance to EPS.

Accuray Price Performance

Accuray stock opened at $2.49 on Thursday. The business has a fifty day moving average price of $2.10 and a 200-day moving average price of $1.97. The firm has a market capitalization of $250.41 million, a P/E ratio of -14.65 and a beta of 1.51. The company has a debt-to-equity ratio of 3.59, a current ratio of 1.63 and a quick ratio of 0.87. Accuray has a one year low of $1.40 and a one year high of $2.95.

Analyst Upgrades and Downgrades

Separately, StockNews.com downgraded shares of Accuray from a “buy” rating to a “hold” rating in a report on Friday, November 15th.

Accuray Company Profile

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.